NO20020931L - Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger - Google Patents

Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger

Info

Publication number
NO20020931L
NO20020931L NO20020931A NO20020931A NO20020931L NO 20020931 L NO20020931 L NO 20020931L NO 20020931 A NO20020931 A NO 20020931A NO 20020931 A NO20020931 A NO 20020931A NO 20020931 L NO20020931 L NO 20020931L
Authority
NO
Norway
Prior art keywords
pyrrolo
nucleoside analogs
pyrimidine nucleoside
substituents
preparations
Prior art date
Application number
NO20020931A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020931D0 (no
Inventor
Guangyi Wang
Robert Tam
Zbigniew Pietrzkowski
Original Assignee
Icn Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn Pharmaceuticals filed Critical Icn Pharmaceuticals
Publication of NO20020931D0 publication Critical patent/NO20020931D0/no
Publication of NO20020931L publication Critical patent/NO20020931L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
NO20020931A 1999-08-27 2002-02-26 Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger NO20020931L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15123399P 1999-08-27 1999-08-27
PCT/US2000/022674 WO2001027114A1 (en) 1999-08-27 2000-08-17 PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS

Publications (2)

Publication Number Publication Date
NO20020931D0 NO20020931D0 (no) 2002-02-26
NO20020931L true NO20020931L (no) 2002-02-26

Family

ID=22537871

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020931A NO20020931L (no) 1999-08-27 2002-02-26 Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger

Country Status (18)

Country Link
EP (1) EP1212326A4 (ru)
JP (1) JP2003511454A (ru)
KR (1) KR20020092904A (ru)
CN (1) CN1384834A (ru)
AU (1) AU769578B2 (ru)
BR (1) BR0013642A (ru)
CA (1) CA2381297A1 (ru)
HR (1) HRP20020163A2 (ru)
HU (1) HUP0301875A2 (ru)
IL (1) IL147908A0 (ru)
MX (1) MXPA02001753A (ru)
NO (1) NO20020931L (ru)
PL (1) PL354094A1 (ru)
RU (1) RU2002103501A (ru)
SI (1) SI20819A (ru)
SK (1) SK1772002A3 (ru)
WO (1) WO2001027114A1 (ru)
ZA (1) ZA200201567B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
JP2003183283A (ja) * 2001-12-18 2003-07-03 Takeda Chem Ind Ltd 縮合インドール化合物、その製造法および用途
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN101851241B (zh) * 2010-07-02 2012-05-23 西安交通大学 一种抗肿瘤化合物及其制备方法和其用途
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
CN102286048A (zh) * 2011-06-24 2011-12-21 吉林大学 4-氨基-6-(3-(3-溴苯基)苯基)-5-氰基-7-(β-L-呋喃木糖)吡咯并[2, 3-d]嘧啶、同类衍生物及用于制备抗肿瘤药物
US9073960B2 (en) 2011-12-22 2015-07-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
EP3623364A1 (en) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
MX2018003212A (es) * 2015-09-23 2018-07-06 Merck Sharp & Dohme Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
JP2021509907A (ja) 2018-01-09 2021-04-08 リガンド・ファーマシューティカルズ・インコーポレイテッド アセタール化合物およびその治療的使用
EP3794012B1 (en) 2018-05-15 2023-10-18 Illumina Inc. Compositions and methods for chemical cleavage and deprotection of surface-bound oligonucleotides
KR20210145787A (ko) 2019-04-02 2021-12-02 알리고스 테라퓨틱스 인코포레이티드 Prmt5를 표적으로 하는 화합물
KR102639275B1 (ko) * 2021-06-08 2024-02-21 퓨쳐메디신 주식회사 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988338A (en) * 1974-04-24 1976-10-26 Wisconsin Alumni Research Foundation 4-Substituted amino-2-substituted thio-pyrrolo-[2,3-d]pyrimidine derivatives
US4892865A (en) * 1987-12-01 1990-01-09 The Regents Of The University Of Michigan Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US5674998A (en) * 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
CA2154681A1 (en) * 1993-02-03 1994-08-18 Mark David Erion Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
US5665721A (en) * 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
CN1233254A (zh) * 1996-10-16 1999-10-27 Icn药品公司 嘌呤l-核苷、其类似物及其用途

Also Published As

Publication number Publication date
RU2002103501A (ru) 2003-09-10
EP1212326A1 (en) 2002-06-12
AU7061800A (en) 2001-04-23
CA2381297A1 (en) 2001-04-19
NO20020931D0 (no) 2002-02-26
WO2001027114A1 (en) 2001-04-19
JP2003511454A (ja) 2003-03-25
KR20020092904A (ko) 2002-12-12
HRP20020163A2 (en) 2004-02-29
SK1772002A3 (en) 2002-10-08
AU769578B2 (en) 2004-01-29
IL147908A0 (en) 2002-08-14
BR0013642A (pt) 2002-05-07
HUP0301875A2 (hu) 2003-09-29
ZA200201567B (en) 2003-07-30
SI20819A (sl) 2002-08-31
EP1212326A4 (en) 2003-08-20
PL354094A1 (en) 2003-12-29
MXPA02001753A (es) 2002-10-23
CN1384834A (zh) 2002-12-11

Similar Documents

Publication Publication Date Title
NO20020931L (no) Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger
WO2002100354A3 (en) Pyrrolo[2,3-d]pyrimidine nucleoside analogs
EP2011499A3 (en) Pyrrolo[2,3d]Pyrimidine compositions and their use
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
HK1065483A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
MY136242A (en) Purine derivatives
HUP0401777A3 (en) 3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds
NZ513450A (en) Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R,cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene- 1-methanol useful as antiviral agents
TR200002299T2 (tr) Epotilon kompozisyonları.
AP2002002480A0 (en) Purine derivatives.
AP2001002361A0 (en) Purine derivatives.
DK1382339T3 (da) Kompositioner indeholdende pyrrolo 2,3-d pyrimidinderivater
MX9709859A (es) Inhibidores de adenosina cinasa modificados en c-4.
AU7776891A (en) 5-benzyl barbiturate derivatives
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
BR9908391A (pt) Composição antitumural contendo uma combinação sinergìstica de um derivado de antraciclina com um derivado de camptotecina
WO2005007103A3 (en) Use of parthenolide derivatives as antileukemic and cytotoxic agents
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
CA2364251A1 (en) Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
HUP0300219A2 (hu) L-nukleozidokat, L-nukleotidokat és analógjaikat tartalmazó készítmények és alkalmazásuk
ATE250603T1 (de) 1,8-naphthalimid imidazo(4,5,1-de)acridone mit antitumorwirkung
BR0207102A (pt) Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença
CA2355239A1 (en) Pharmaceutical formulations
TR200002293T2 (tr) Farmasötik bileşimler.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application